Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study

Key Points

• Assess the efficacy and tolerability of lenalidomide-dexamethasone in treating refractory Rosai-Dorfman-Destombes disease.
• Conducted a clinical evaluation of treatment outcomes.
• Utilized pharmacophenomic analysis to assess drug response.
• Collaborated with the Coastal Rare Inflammatory Diseases Program and Every Cure.
• Showed significant improvement in disease symptoms after treatment.
• Demonstrated high tolerability with minimal side effects.